Tempest Therapeutics launch shows IDO inhibitors are still hot

The start-up unveils with $70 million in series B funding to develop cancer immunotherapy compounds, including an IDO1 inhibitor

via Chemical & Engineering News: Biological SCENE https://ift.tt/2GmEWli